Stryker Hits New 52-Week High - Analyst Blog
) achieved a new 52-week high, touching $67.36 on May 9, which is
above its previous level of $67.15, and closed at $67.01 on the
same date. The closing price of this orthopedic devices giant
represented a solid one-year return of 27.7% and year-to-date
return of 20.4%.
Average volume of shares traded over the last 3 months came in at approximately 1,562K. Currently, the stock trades at a forward P/E of 15.96x, above its peer group P/E of 14.43x.
Impressive first-quarter 2013 results, including an earnings surprise of 1.98% and the recent completion of the acquisition of a leading China-based trauma manufacturing company, Trauson Holdings, were the primary growth drivers for Stryker.
On Apr 24, Stryker reported its first-quarter earnings per share of $1.03 beating the Zacks Consensus Estimate by 2 cents and the year-ago earnings by 4.0%. Organic revenue growth along with cost curtailment efforts by the company's global quality and operations group led to the year-over-year growth.
Stryker's strong business fundamentals, well-diversified product portfolio and expanding foothold in emerging markets through acquisitions are expected to drive future growth. Moreover, the company remains committed to delivering incremental return to investors via share repurchase and dividends.
Recently, in Mar 2013, it completed the acquisition of a leading China-based trauma manufacturing company, Trauson Holdings. Stryker acquired this entity in an effort to strengthen its foothold in the Chinese orthopedic market.
Stryker, with a market-cap of $25.33 billion, is one of the world's largest medical device manufacturers operating in the global orthopedic market. The recent stability in the domestic recon market and turnaround of its European business should improve results in 2013.
Stocks to Consider
Stryker carries a Zacks Rank #3 (Hold). With Stryker's shares trading at all-time highs, any upside from here may be limited. Other medical stocks such as Conceptus ( CPTS ), TG Therapeutics ( TGTX ) and AtriCure ( ATRC ) warrant a look. While Conceptus carries a Zacks Rank #1 (Strong Buy), the other two stocks carry a Zacks Rank #2 (Buy).
ATRICURE INC (ATRC): Free Stock Analysis Report
CONCEPTUS INC (CPTS): Free Stock Analysis Report
STRYKER CORP (SYK): Free Stock Analysis Report
TG THERAPEUTICS (TGTX): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research